Form 4: Tourmaline Bio CTO Sells Shares in Novartis Merger

Tourmaline Bio's Chief Technology Officer, Susan Dana Jones, disposed of common stock and stock options following the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Susan Dana Jones, Chief Technology Officer of Tourmaline Bio, Inc. (TRML), reported the disposal of common stock and employee stock options.
• The transactions occurred on October 28, 2025, pursuant to the Agreement and Plan of Merger with Novartis AG.
• Merger Sub, an indirect wholly owned subsidiary of Novartis AG, completed a cash tender offer to acquire all outstanding shares of Tourmaline Bio for $48.00 in cash per share.
• Jones disposed of 19,782 shares of common stock and 3,152 restricted shares, each tendered for $48.00 in cash.
• Employee stock options with exercise prices of $7.9, $9.46, and $17 were canceled and converted into a cash payment equal to the difference between the $48.00 merger consideration and the respective exercise price, multiplied by the number of shares underlying the options.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person, who successfully monetized their equity holdings at a fixed, favorable cash price due to the merger. For the company's shareholders, it represents a successful exit through acquisition.

Positives

• The reporting person, Susan Dana Jones, successfully monetized her equity holdings in Tourmaline Bio, Inc. at a fixed cash price of $48.00 per share.
• Employee stock options, including those with exercise prices significantly below the merger consideration, were converted into cash payments, providing a clear financial benefit to the option holder.

Negatives

• The reporting person no longer holds any direct beneficial ownership in Tourmaline Bio, Inc. following the completion of the merger.

Future Outlook

This filing reports a completed transaction and does not provide forward-looking statements or guidance for Tourmaline Bio, Inc. as an independent entity.

Industry Context

The acquisition of Tourmaline Bio, Inc. by Novartis AG represents a strategic move by a major pharmaceutical company to integrate a smaller biotechnology firm, likely to enhance its pipeline or technological capabilities. This reflects ongoing consolidation trends within the life sciences sector.

Stakeholder Impact

• Shareholders of Tourmaline Bio, Inc. received $48.00 in cash per share, representing a definitive return on their investment.
• Employees holding stock options, such as the Chief Technology Officer, had their options converted into cash payments, providing a liquidity event.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, SEC Form 4, Insider Transaction, Stock Options, Common Stock, Chief Technology Officer